Entecavir: A new treatment option for chronic hepatitis B
- 7 March 2006
- journal article
- review article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36 (1) , 8-12
- https://doi.org/10.1016/j.jcv.2006.01.010
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B PatientsGastroenterology, 2005
- Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJournal of Hepatology, 2005
- Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2005
- Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir†Hepatology, 2005
- Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus InfectionJournal of Virology, 2005
- Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year studyJournal of Hepatology, 2005
- Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis InfectionThe Journal of Infectious Diseases, 2001
- Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology, 2001
- Efficacy of the Carbocyclic 2′-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus InfectionAntimicrobial Agents and Chemotherapy, 1998
- BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitroBioorganic & Medicinal Chemistry Letters, 1997